{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:02:04Z","timestamp":1794340924947,"version":"4.9.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.ejphar.2008.06.063","type":"journal-article","created":{"date-parts":[[2008,6,20]],"date-time":"2008-06-20T08:06:09Z","timestamp":1213949169000},"page":"136-141","source":"Crossref","is-referenced-by-count":26,"title":["Validation of a rat in vivo [3H]M100907 binding assay to determine a translatable measure of 5-HT2A receptor occupancy"],"prefix":"10.1016","volume":"591","author":[{"given":"Christopher S.","family":"Knauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Osgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Buist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.F.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Grimwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.06.063_bib1","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/rcm.2537","article-title":"Liquid chromatography\/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma","volume":"20","author":"Bhatt","year":"2006","journal-title":"Rapid Communications in Mass Spectrometry"},{"key":"10.1016\/j.ejphar.2008.06.063_bib2","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/S0924-977X(98)80422-7","article-title":"The safety, tolerability, pharmacokinetics and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers","volume":"8","author":"Brunner","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2008.06.063_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01276460","article-title":"The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis","volume":"100","author":"Carlsson","year":"1995","journal-title":"J. Neural. Transm. Gen. Sect."},{"key":"10.1016\/j.ejphar.2008.06.063_bib4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0028-3908(99)00049-0","article-title":"In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats","volume":"38","author":"Chaki","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.06.063_bib5","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1097\/00004714-199502001-00004","article-title":"Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients","volume":"15","author":"Farde","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2008.06.063_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0893-133X(97)00044-4","article-title":"Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography","volume":"17","author":"Grunder","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.06.063_bib7","series-title":"NIH Publication No. 85-23","article-title":"Guide for the care and use of laboratory animals","author":"Institute of Laboratory Animal Resources","year":"1985"},{"key":"10.1016\/j.ejphar.2008.06.063_bib8","first-page":"208","article-title":"PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907","volume":"39","author":"Ito","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejphar.2008.06.063_bib9","first-page":"85","article-title":"Asenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine","volume":"81","author":"Jentsch","year":"2006","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2008.06.063_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.063_bib10","first-page":"968","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.06.063_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0026-895X(25)14623-3","article-title":"[3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role","volume":"21","author":"Leysen","year":"1982","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.063_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/PL00005075","article-title":"Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907","volume":"356","author":"Lopez-Gimenez","year":"1997","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.063_bib13","doi-asserted-by":"crossref","first-page":"PL187","DOI":"10.1016\/0024-3205(96)00013-6","article-title":"[11C]MDL 100907, a radioligand for selective imaging of 5-HT(2A) receptors with positron emission tomography","volume":"58","author":"Lundkvist","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2008.06.063_bib14","first-page":"238","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.06.063_bib15","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.06.063_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02251294","article-title":"High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET","volume":"110","author":"Nordstrom","year":"1993","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.ejphar.2008.06.063_bib17","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstrom","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.063_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02251280","article-title":"5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone","volume":"110","author":"Nyberg","year":"1993","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.ejphar.2008.06.063_bib19","first-page":"1195","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"8","author":"Potkin","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.063_bib20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2008.06.063_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.ejphar.2008.06.063_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0006-8993(93)91535-Z","article-title":"Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography","volume":"631","author":"Schotte","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.06.063_bib23","unstructured":"Shahid, M., Walker, G.B., Zorn, S.H., Wong, E.H.F., in press. Asenapine: a Novel Psychopharmacologic Agent with a Unique Human Receptor Signature. J. Psychopharmacol. [February 28, 2008, Electronic publication ahead of print]."},{"key":"10.1016\/j.ejphar.2008.06.063_bib24","first-page":"684","article-title":"Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.06.063_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology (Berl)"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908006778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908006778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T19:01:13Z","timestamp":1738263673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908006778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":26,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0014299908006778"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.063","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}